Amicus Therapeutics, Inc. Announces Third Quarter 2011 Financial Results

CRANBURY, N.J., Nov. 1, 2011 (GLOBE NEWSWIRE) -- Amicus Therapeutics (Nasdaq:FOLD), a biopharmaceutical company at the forefront of developing therapies for rare diseases, today announced financial results for the third quarter ended September 30, 2011. The Company also highlighted recent and upcoming milestones surrounding Phase 3 global registration studies of Amigal™ (migalastat HCl) for Fabry disease, and ongoing Phase 2 studies to evaluate the co-administration of pharmacological chaperones with enzyme replacement therapy (PC-ERT) for Fabry and Pompe diseases.